Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome.
Eustáquio
Alessandra S
AS
Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0204, USA.
Moore
Bradley S
BS
D001665:Binding Sites; D001685:Biological Factors / Q000096:biosynthesis* / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005818:Genetic Engineering; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000737:chemistry* / Q000494:pharmacology; D007769:Lactams / Q000737:chemistry / Q000494:pharmacology; D007783:Lactones / Q000737:chemistry* / Q000494:pharmacology; D061988:Proteasome Inhibitors; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology; D012441:Saccharomyces cerevisiae / Q000201:enzymology; D013329:Structure-Activity Relationship
D001685:Biological Factors; D006845:Hydrocarbons, Fluorinated; D007769:Lactams; D007783:Lactones; D061988:Proteasome Inhibitors; D011758:Pyrroles; C529938:fluorosalinosporamide; C475865:marizomib; C504698:salinosporamide B